Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Blinatumomab Coverage Update: Prior Auth | …
    Ask Trek AI about this page
    ModifiedAnthemPolicy CC-0126

    Blincyto (blinatumomab) — Coverage Criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0126 alerts

    Get alerted when Policy CC-0126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical criteria governing prior authorization and medical necessity for Blincyto (blinatumomab) for treatment of CD19+ B-cell acute lymphoblastic leukemia (ALL) under the medical benefit; applies to Anthem members and providers requesting coverage.

    Policy Summary
    PayerAnthem
    PolicyBlincyto (blinatumomab) — Coverage Criteria
    Policy CodePolicy CC-0126
    Change TypeClarified (NCCN 2A/TKI use) and editorial updates
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review DateFeb 20, 2026
    Key ActionObtain prior authorization and submit documentation supporting CD19+ B‑cell precursor ALL diagnosis and the specific indication (eg, relapsed/refractory, MRD ≥0.1%, Ph+ with TKI, consolidation/maintenance, or infant KMT2A regimen).
    SourceLink
    POLICY UPDATE CHANGES

    Updated NCCN 2A recommendation for use with a TKI to clarify use in Philadelphia chromosome positive disease.

    Wording and formatting criteria updates across the document.

    Black boxSafety

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J9039Billing code
    C91.00-C91.02Diagnosis range
    NCCN 2AGuideline level

    Coverage Criteria for Blincyto (blinatumomab)

    Requests for Blincyto (blinatumomab) for the treatment of diffuse large B‑cell lymphoma (DLBCL) are not approved under these criteria.

    Use of Blincyto (blinatumomab) for any indication that does not meet the specified coverage criteria (including any other unspecified indications) is not approved.

    Coding and Diagnostic Codes

    HCPCSHCPCS
    J9039Injection, blinatumomab, 1 microgram [Blincyto]
    ICD-10 DiagnosisICD-10
    C91.00-C91.02Acute lymphoblastic leukemia [ALL]
    inv-06: Minimal residual disease (MRD) — numeric threshold
    MRD threshold>= 0.1% (Minimal residual disease following first or second complete response)
    ContextApplies to B-cell ALL in first or second complete remission after induction therapy when MRD is greater than or equal to 0.1%
    Source authorityFDA-approved indication referenced in policy; also reflected in coverage criteria (Label, NCCN 1, NCCN 2A)

    Provider Actions, Documentation, and Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required: Prior authorization is required for Blincyto (blinatumomab). Approval is contingent on meeting the policy clinical criteria (patient under 19 years of age OR diagnosis of CD19+ B‑cell precursor ALL with one of the listed indications).

    • Prior authorization required before initiation of therapy
    • Approval contingent on meeting criteria: age <19 OR CD19+ B‑cell precursor ALL with specified indications
    Step Therapy

    Step Therapy

    Step therapy: There is no required step‑therapy sequence of prior systemic agents in this policy. Coverage is determined by the clinical criteria described in the policy and alignment with FDA‑approved indications and NCCN recommendations (including NCCN 1 and NCCN 2A listed uses).

    • No mandatory prior therapies or step‑up sequence required by this policy

    Background on Blinatumomab

    Blincyto (blinatumomab) is a bispecific T‑cell engager that links CD3 on T cells with CD19 on B cells to facilitate immune‑mediated lysis of malignant B cells. It is used clinically for CD19+ B‑cell precursor acute lymphoblastic leukemia (ALL) in specific situations such as relapsed/refractory disease, as consolidation or maintenance (including maintenance alternating with POMP), for minimal residual disease (MRD) ≥ 0.1% after first or second complete response, and in combination with TKIs for Ph+ disease or with interfant regimens for infants with KMT2A rearrangement per NCCN guidance.

    Definitions

    inv-12: Complete Response (CR) — definition entry
    DefinitionComplete Response (CR): The disappearance of all signs of cancer as a result of treatment; also called complete remission; does not indicate the cancer has been cured.
    SynonymComplete Remission (CR)
    Clinical noteCR may be followed by assessment of MRD to guide further therapy per policy (e.g., MRD >= 0.1%).

    Line of Therapy

    Line of Therapy Classification

    Requests for Blincyto (blinatumomab) may be approved when the following criteria are met:

    Age criterion: Individual is under 19 years of age

    Pediatric approval allowed as standalone criterion

    Adult/pediatric CD19+ disease indications

    • Indications: A: Relapsed or refractory disease; OR B: Blinatumomab used in combination with a tyrosine kinase inhibitor (bosutinib, dasatinib, imatinib, nilotinib, or ponatinib) for Philadelphia chromosome positive (Ph+) disease; OR C: Minimal residual disease (MRD) >= 0.1% following a first or second complete response to induction therapy; OR D: As consolidation therapy; OR E: Used as maintenance therapy as a single agent alternating with POMP (prednisone, vincristine, methotrexate, and mercaptopurine); OR F: Used in combination with interfant regimens for infant ALL with KMT2A (11q23) rearranged

      NCCN label references: 1, 2A depending on indication

    Biomarker and Genetic Requirements

    inv-14: CD19 — biomarker requirement entry
    Biomarker requirementCD19 positive (CD19+) B-cell precursor acute lymphoblastic leukemia is required for use of blinatumomab due to its molecular target.
    RoleDetermines eligibility for Blincyto; therapy should only be used in CD19+ B-cell ALL.
    DocumentationClinical documentation must support diagnosis of CD19+ B-cell precursor ALL (ICD-10 C91.00-C91.02) when requesting prior authorization.
    inv-15: KMT2A (11q23) rearrangement — biomarker requirement entry
    Biomarker requirementKMT2A (11q23) rearrangement is required when blinatumomab is used in combination with Interfant regimens for infant ALL (NCCN 2A).
    Use caseSpecifically applies to infant acute lymphoblastic leukemia being treated with Interfant regimens plus blinatumomab.

    Covered Regimens and Combinations

    RegimenIndication / NotesCoverage
    Blinatumomab + bosutinibUse in combination with a tyrosine kinase inhibitor (TKI) for Philadelphia chromosome–positive (Ph+) B‑ALL per NCCN 2A.Covered
    Blinatumomab + dasatinibUse in combination with a tyrosine kinase inhibitor (TKI) for Philadelphia chromosome–positive (Ph+) B‑ALL per NCCN 2A.Covered
    Blinatumomab + imatinibUse in combination with a tyrosine kinase inhibitor (TKI) for Philadelphia chromosome–positive (Ph+) B‑ALL per NCCN 2A.Covered
    Blinatumomab + nilotinibUse in combination with a tyrosine kinase inhibitor (TKI) for Philadelphia chromosome–positive (Ph+) B‑ALL per NCCN 2A.Covered
    Blinatumomab + ponatinibUse in combination with a tyrosine kinase inhibitor (TKI) for Philadelphia chromosome–positive (Ph+) B‑ALL per NCCN 2A.Covered
    RegimenIndication / NotesCoverage
    Blinatumomab as single agent alternating with POMP (prednisone, vincristine, methotrexate, mercaptopurine)Used as maintenance therapy alternating with POMP per NCCN guidance; applicable for CD19+ B‑cell precursor ALL.Covered
    RegimenIndication / NotesCoverage
    Blinatumomab in combination with Interfant regimensRecommended by NCCN (2A) for infant ALL with KMT2A (11q23) rearrangement; Interfant denotes infant‑specific chemotherapy protocols described in guidelines.Covered
    Policy Summary
    PayerAnthem
    PolicyBlincyto (blinatumomab) — Coverage Criteria
    Policy CodePolicy CC-0126
    Change TypeClarified (NCCN 2A/TKI use) and editorial updates
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review DateFeb 20, 2026
    Key ActionObtain prior authorization and submit documentation supporting CD19+ B‑cell precursor ALL diagnosis and the specific indication (eg, relapsed/refractory, MRD ≥0.1%, Ph+ with TKI, consolidation/maintenance, or infant KMT2A regimen).
    SourceLink
    On This Page
    Coverage Criteria for Blincyto (blinatumomab)Coding and Diagnostic CodesProvider Actions, Documentation, and Prior AuthorizationBackground on BlinatumomabDefinitionsLine of TherapyBiomarker and Genetic RequirementsCovered Regimens and Combinations
  1. Coverage contingent on meeting listed clinical criteria and NCCN/FDA indicated uses
  2. Documentation Required

    Required Documentation

    Required documentation: Submit documentation that verifies the diagnosis, supporting clinical details, and relevant ICD‑10 code(s). Include treatment intent and specific indication justification (relapsed/refractory disease, Ph+ disease with TKI combination, MRD ≥ 0.1% after first/second complete response, consolidation, maintenance alternating with POMP, or use with Interfant regimens for infant ALL with KMT2A rearrangement).

    • Include member age and proof of CD19+ B‑cell precursor ALL when applicable
    • Provide documentation of the specific indication being treated (one of the policy‑listed indications)
    • Include relevant ICD‑10 diagnosis code(s) (e.g., C91.00‑C91.02)
    Denial Risk

    Denial Triggers

    Denial triggers: Requests will be denied if the clinical criteria are not met. Common denial reasons include use for non‑CD19+ B‑cell ALL diagnoses (for example DLBCL), indications not listed in the policy, lack of documentation confirming CD19 positivity or the specific policy indication, or failure to provide required supporting records.

    • Not CD19+ B‑cell precursor ALL when required by criteria
    • Indication is diffuse large B‑cell lymphoma (DLBCL) or other non‑covered diagnoses
    • Insufficient documentation of diagnosis, CD19 status, MRD level, prior response status, or use with required combination regimens
    ref': 'b0_0
    title': 'Approved Indications (including pediatric allowance)
    ref": "b0_0",
    title": "Approved Indications (including pediatric allowance)",
    Guideline referenceNCCN 2A recommendation cited in policy for this combination in KMT2A-rearranged infant ALL.